Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1356068-62-6 | MDL No. : | MFCD16996767 |
Formula : | C16H22BN3O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KMOMTJKORSQJNI-UHFFFAOYSA-N |
M.W : | 315.18 | Pubchem ID : | 53217326 |
Synonyms : |
|
Num. heavy atoms : | 23 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.62 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 91.15 |
TPSA : | 67.61 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -7.06 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.64 |
Log Po/w (WLOGP) : | 0.71 |
Log Po/w (MLOGP) : | 0.0 |
Log Po/w (SILICOS-IT) : | 1.27 |
Consensus Log Po/w : | 0.72 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.89 |
Solubility : | 0.408 mg/ml ; 0.00129 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.67 |
Solubility : | 0.669 mg/ml ; 0.00212 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.88 |
Solubility : | 0.0417 mg/ml ; 0.000132 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 3.36 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 | UN#: | |
Hazard Statements: | H315-H319 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
78% | With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate In toluene at 95℃; for 5h; Inert atmosphere; | 2 Intermediate A5. 2-morpholino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-cyano-pyridine Bis(pinacolato)diboron (682 mg, 2.69 mmol), KOAc (659 mg, 6.71 mmol) and PdCl2(dppf).CH2Cl2 (91.4 mg, 0.110 mmol) were added to a solution of 5-bromo-2-morpholinonicotinonitrile (600 mg, 2.24 mmol) in toluene (10 mL) under Ar atmosphere. The reaction mixture was stirred at 95° C. for 5 h. The reaction mixture was diluted with EtOAc and washed with water (3×20 mL) and brine (2×20 mL). The organic layer was dried (MgSO4), filtered and concentrated. The residue was purified on ISCO (0-30% EtOAc in Hexanes) to provide the desired product (550 mg, 78% yield). LC-MS, Rt=0.407, m/z=234.1 [boronic acid]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate / acetonitrile; water / 3 h / 95 °C / Inert atmosphere 2: ammonium hydroxide; hydrogen / water; ethanol / 20 h / 20 °C / 760.05 Torr / Sealed tube |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 3 steps 1: dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate / acetonitrile; water / 3 h / 95 °C / Inert atmosphere 2: ammonium hydroxide; hydrogen / water; ethanol / 20 h / 20 °C / 760.05 Torr / Sealed tube 3: HATU; 4-methyl-morpholine / N,N-dimethyl-formamide / 1 h / 20 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
35% | With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium carbonate In water; acetonitrile at 95℃; for 3h; Inert atmosphere; | 9.1 Example 9 (Table 1, B223) (0244) Example 9 N-((5-(6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-2-yl)-2-morpholinopyridin-3-yl)methyl)-3-methoxy-4-methylbenzamide 2-Morpholino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile (Intermediate A5, 550 mg, 1.74 mmol), PdCl2(dppf).CH2Cl2 (43.7 mg, 0.050 mmol) and K2CO3 (2.5 M aq solution, 1.28 mL, 3.21 mmol) were added to a solution of 2-bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole (200 mg, 1.07 mmol) in CH3CN (0.6 mL) under Ar atmosphere. The reaction mixture was stirred at 95° C. for 3 h. The reaction mixture was concentrated (there was solid). The residue was purified on ISCO (0% to 20% MeOH in CH2Cl2) to provide the desired product (110 mg, 35% yield). 1H NMR (400 MHz, MeOH-d4) δ 8.71 (d, J=2.2 Hz, 1H), 8.19 (d, J=2.4 Hz, 1H), 7.46 (s, 1H), 4.07 (t, J=7.2 Hz, 2H), 3.84-3.81 (m, 4H), 3.66-3.63 (m, 4H), 2.90 (t, J=7.4 Hz, 2H), 2.65 (pent, J=7.4 Hz, 2H); LC-MS, Rt=0.680, m/z=296.1 [M+H]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: potassium carbonate / N,N-dimethyl-formamide / 0.5 h / 95 °C / Inert atmosphere 2: potassium acetate; dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2 / toluene / 5 h / 95 °C / Inert atmosphere |
[ 1073372-03-8 ]
4-(3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine
Similarity: 0.94
[ 1356068-47-7 ]
2-(Diethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.93
[ 1356068-47-7 ]
2-(Diethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.93
[ 1356068-52-4 ]
2-(Pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.91
[ 1356068-52-4 ]
2-(Pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.91
[ 1073372-03-8 ]
4-(3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine
Similarity: 0.94
[ 1356068-47-7 ]
2-(Diethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.93
[ 1356068-52-4 ]
2-(Pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.91
[ 1356068-53-5 ]
2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.90
[ 1356068-47-7 ]
2-(Diethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.93
[ 1356068-52-4 ]
2-(Pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.91
[ 1356068-53-5 ]
2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.90
[ 1073372-03-8 ]
4-(3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine
Similarity: 0.94
[ 1073372-03-8 ]
4-(3-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)morpholine
Similarity: 0.94
[ 1356068-47-7 ]
2-(Diethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.93
[ 1356068-52-4 ]
2-(Pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.91
[ 1356068-53-5 ]
2-(Piperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.90
[ 1346809-52-6 ]
2-(Ethylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile
Similarity: 0.89